The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | CD19-CAR-T therapy for CLL with Richter’s transformation
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, shares the findings from a single center Phase II trial of CD19-targeted CAR-T cell therapy in patients with chronic lymphocytic leukemia (CLL) with disease transformation. Those enrolled in the trial included patients with Richter’s transformation, accelerated CLL and prolymphocytic transformations. The therapy was demonstrated as safe and produced a high complete remission rate. CAR-T therapy is a promising option for these patients, but longer-term follow-up is needed to understand the durability of remission. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
